Rznomics
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Rznomics develops RNA-based medicines, therapies that work by editing the genetic messages inside cells to treat disease.
It is a clinical-stage biotech listed on KOSDAQ, South Korea's tech-focused stock exchange. Its core platform uses a naturally occurring RNA enzyme, derived from a single-celled organism, that can seek out a disease-linked RNA target, cut it, and splice in a corrective gene sequence in a single step. The company's primary revenue model is licensing this platform technology to partners in exchange for upfront fees, development milestone payments, and royalties.
Summary is AI-generated and may contain errors · figures from DART filings
Rznomics in five facts
What does Rznomics do?
Rznomics develops RNA-based medicines, therapies that work by editing the genetic messages inside cells to treat disease.
Where is Rznomics listed and in which sector?
Rznomics (Korean name: 알지노믹스) trades under KRX code 476830 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is Rznomics?
Its market capitalisation was US$531.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Rznomics's latest annual revenue and operating profit?
For fiscal year 2025, Rznomics reported revenue of US$6M, an operating loss of US$11M and a net loss of US$78.4M, per its annual report on DART (data retrieved from DART on 2026-06-04).
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-06-04
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (standard)Oct 15
- Report on securities held by executives/major shareholdersOct 8
- Report on securities held by executives/major shareholdersOct 8
- Report on securities held by executives/major shareholdersOct 8
- Report on large shareholdings (5% rule) (abbreviated)Sep 9
- Ex-rights (bonus issue)Capital raise · Jun 26
- Trading suspension (bonus issue)Capital raise · Jun 15
- Material event report (bonus issue)Capital raise · Jun 15
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)Earnings · Jan 20